CUE241115C4000
- 0.00
- 0.000.00%
Cue Biopharma Newsroom
A Quick Look at Today's Ratings for Cue Biopharma(CUE.US), With a Forecast Between $2 to $6
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Cue Biopharma Analyst Ratings
Piper Sandler Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $3
Stifel Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $4
Analysts Have Conflicting Sentiments on These Healthcare Companies: Perrigo Company (PRGO), Cue Biopharma (CUE) and United Therapeutics (UTHR)
Stifel Nicolaus Sticks to Their Buy Rating for Cue Biopharma (CUE)
Cue Biopharma Price Target Cut to $2.00/Share From $15.00 by JMP Securities
Cue Biopharma Analyst Ratings
Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3
Piper Sandler Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $3
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $2
Cue Biopharma Receives 'Buy' Rating Amid Strategic Shift and Promising Autoimmune Therapeutics Pipeline
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Oppenheimer: Maintaining the Cue Biopharma (CUE.US) rating, adjusted from superior to superior market ratings, and adjusted the target price from $10.00 to $10.00.
Cue Biopharma Analyst Ratings
Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target
Oppenheimer Remains a Buy on Cue Biopharma (CUE)